Clinical Trial Update: Lenalidomide After Failure of Hypomethylating Agents in Myelodysplastic Syndrome [Phase 2]

View source ↗

Summary

Clinical trial update on lenalidomide for myelodysplastic syndrome after failure of hypomethylating agents; Phase 2 study status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndrome

Drugs mentioned

• Revlimid (lenalidomide)

Snippet

Sponsor: Ulsan University Hospital | Conditions: Myelodysplastic Syndrome | Phase 2 | Status: UNKNOWN